Analysts Perspectives: Dynavax Technologies (DVAX)

Adjust Comment Print

According to analysts Dynavax Technologies (NASDAQ:DVAX)'s minimum EPS for the current quarter is at $-0.48 and can go high up to $1.24. They expect this year's earnings to fall -41.1% year-over-year to -$1.72, followed by -40.12% decline in the next year to -$1.03. While in the same Quarter Previous year, the Actual EPS was $-0.56. During the same period last year, the company posted ($0.90) earnings per share. analysts anticipate that Dynavax Technologies Corporation will post -1.72 earnings per share for the current year.

In the most updated research from a number of analysts on Wall Street, the company gets 5 Buys and 0 Sell among 5 analysts. Dynavax Technologies Corp. The business had revenue of $2.65 million for the quarter, compared to the consensus estimate of $1.58 million.

Dynavax Technologies Corporation (DVAX) has the market capitalization of $1.1 Billion. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.15. The days to cover decreased to 5.0 and the percentage of shorted shares was 0.13% on October 13. Dynavax Technologies Corporation had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company's stock worth $19,538,000 after buying an additional 199,004 shares during the period.

DVAX has been the subject of a number of recent analyst reports.

Dynavax Technologies Corporation (NASDAQ:DVAX)'s earnings per share has been growing at a 5.5 percent rate over the past 5 year when average revenue increase was noted as -12.6 percent. William Blair reissued an "outperform" rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a "neutral" rating to an "overweight" rating and increased their price target for the company from $6.00 to $27.00 in a research note on Monday, July 31st.

Panthers rookie Curtis Samuel out for remainder of season
The Panthers announced the second-round pick will undergo season-ending ankle surgery and will be placed on injured reserve. As a junior at Ohio State in 2016, Samuel was used as the Buckeyes' H-Back. "I think it's kind of a collective effort".


November 9 investment analysts at Cantor Fitzgerald held the stock rating at "Buy" projecting a price of $25.00. The third largest holder is Gmt Capital Corp, which now holds $61.91 million worth of this stock and that ownership represents almost 5.63% of its market capitalization. If you are viewing this report on another domain, it was illegally copied and reposted in violation of USA & global copyright & trademark legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/11/14/dynavax-technologies-corporation-dvax-expected-to-announce-earnings-of-0-30-per-share.html. Dynavax Technologies Corporation (NASDAQ:DVAX)'s short interest is 7.63 million shares, or 17.27% of the float. The portion of a company's profit allocated to each outstanding share of common stock was $1.64 a share in the trailing twelve months. The recent change has given its price a -13.52% deficit over SMA 50 and -24.95% deficit over its 52-week high.

Large investors have recently made changes to their positions in the company.

On the other hand Dynavax Technologies (NASDAQ:DVAX) has Relative Strength Index (RSI 14) of 35.75 along with Average True Range (ATR 14) of 1.48.

Insider ownership increased by a total of 0 shares, which suggests that DVAX's key executives are feeling more optimistic about the outlook for the stock. Candriam Luxembourg S.C.A. bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at approximately $5,066,000. Rathbone Brothers plc purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter valued at approximately $105,000.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company.

Comments